Mizuho raises Boston Scientific target to $130, maintains Outperform
Securities adjusted its outlook on Boston Scientific (NYSE:BSX) shares, raising the price target to $130 from $110 while maintaining an Outperform rating. The revision follows a series of positive developments reported by the medical device company,
Boston Scientific price target raised to $122 from $119 at Raymond James
Raymond James analyst Jayson Bedford raised the firm’s price target on Boston Scientific (BSX) to $122 from $119 and keeps a Strong Buy rating
Boston Scientific (NYSE:BSX) Price Target Raised to $115.00
Boston Scientific (NYSE:BSX – Free Report) had its price objective raised by Piper Sandler from $95.00 to $115.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have an overweight rating on the medical equipment provider’s stock.
Boston Scientific sees higher-than-expected 2025 profit on strong demand
Medical device maker Boston Scientific forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.
Boston Scientific price target raised to $117 from $101 at Canaccord
Canaccord raised the firm’s price target on Boston Scientific (BSX) to $117 from $101 and keeps a Buy rating on the shares. The firm said they
Boston Scientific 4Q Profit Up on Strong Cardio Device Sales
Boston Scientific said its fourth-quarter net income rose 12% amid robust demand for its stents, catheters and other cardiology devices. The Marlborough, Mass., medical-device maker posted fourth-quarter earnings of $566 million, or 38 cents a share, up from $504 million, or 34 cents a share, a year earlier.
Boston Scientific remains bullish despite tariffs with sales buoyed by Minnesota tech
Climbing sales for a made-in-Minnesota system treating atrial fibrillation helped sustain Boston Scientific’s streak of bullish results as the company brushed off tariffs. The medtech company’s pulse field ablation system,
Here's Why Boston Scientific (BSX) is a Strong Growth Stock
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank,
Hosted on MSN43m
Farapulse boosts Boston Scientific’s Q4 electrophysiology sales by 172%
Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.
Boston Scientific closes its year of PFA on a high note
Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...
MassDevice1d
Boston Scientific expects double-digit sales growth in 2025 following Street-beating Q4
Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...
5BSX : Boston Scientific Clocks 22% Jump In Q4 Sales On Strong...
Boston Scientific posted Q4 revenue of $4.56 billion, surpassing estimates. The company forecasts 2025 sales growth of up to 14.5% and EPS of $2.80-$2.87.
Boston Scientific Corporation (BSX) Q4 2024 Earnings Call Transcript
Boston Scientific Corporation ( NYSE: BSX) Q4 2024 Earnings Conference Call February 5, 2025 8:00 AM ET Jonathan Monson - SVP, IR Michael Mahoney - Chairman and CEO Daniel Brennan - EVP and CFO ...
FierceBiotech1d
Boston Scientific clocks over $1B in Farapulse revenue for the afib therapy's first year
Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the ...
Hosted on MSN1d
How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat
Boston Scientific stock jumped Wednesday after the medtech giant easily beat Wall Street's fourth-quarter expectations and its own guidance.